adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

Press releases

20. August 2018
Pet therapeutic antibody firm adivo announces closure of seed-financing round
German biotech company adivo specializing in generating species-specific therapeutic antibodies for companion animals announces that it received a seed financing from three investors. The adivo team aims to address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in the future. “Now, we are very pleased to have gained three strong and reliable partners that share our vision

Info & Contact

Kathrin Ladetzki-Baehs
+49 (0) 89 588088-471
Markus Waldhuber
+49 (0) 89 588088-478


adivo GmbH
Am Klopferspitz 19
82152 Martinsried/ Planegg

In portfolio

19. Jul 2018

HTGF Manager

Dr. Lena Krzyzak, Principal / Authorized Signatory